The Only Test to Detect EPA

Developed to aid wound assessment and help clinicians target advanced wound care therapies more effectively, WOUNDCHEK™ Protease Status is able to detect EPA (elevated protease activity). As there are no visual cues for EPA, wounds with EPA have so far gone undetected1Snyder R. et al. A survey: The importance of proteases in wound healing and wound assessment. Poster, Wounds UK 2011.

WOUNDCHEK™ Protease Status will help clinicians establish within minutes which wounds may most benefit from a protease modulating therapy, ensuring appropriate and targeted use of these therapies.

WOUNDCHEK™ Protease Status product sizes — Now available in countries accepting CE mark!





WOUNDCHEK™ Protease Status
6 Test Kit

6 tests (all material needed)


Status Control Kit

3 elevated result and
3 low result control swabs


Woundchek Protease Status Specimen Collection Video (the Serena Method)

Woundchek Protease Status Test Procedure Video


The product information on this page is not intended for, or to be used by health care professionals or users in the United States


  • Posters/Articles icon
  • Consensus Documents
  • Symposiums

Posters & Articles

Serena TE, et al, 2016. Defining a new diagnostic assessment parameter for wound care: Elevated protease activity, an indicator of nonhealing, for targeted protease-modulating treatment

Lazaro J., et al, 2016. Elevated levels of matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence

Izzo I., et al, 2014. High matrix metalloproteinase levels are associated with dermal graph failure in diabetic foot ulcers

Frenthoff, E. et al. 2015. Testing and treating for elevated protease activity (EPA) in wound care clinics improves clinical outcome at no additional cost

 Uccioli, L. et al. 2014. The presence of elevated protease activity (EPA) influences the integration of dermal grafts in diabetic foot ulcers

 Gibson, M. et al. 2013. Testing chronic wounds for EPA.  The benefits of testing all wounds, whether assessed as healing or non-healing

 Ivory, 2013. The cost implications of implementing Woundchek Protease Status into clinical practice

 Ivory, 2013. Assessing chronic non healing wounds for elevated protease activity

pdf icon Anichini, R. et al. 2013. Detecting and treating Elevated Protease Activity (EPA) in chronic diabetic wounds

pdf icon Duteille, F. 2013. Evaluation of the use of point-of-care test for proteases to identify patients with increased risk of skin graft failure

pdf icon Nherera, L. et al. 2013. Quantifying the economic value of diagnostics in wound care in the UK

pdf icon International case series: Using Promogran/Promogran Prisma on wounds with elevated protease activity: case studies. London: Wounds International, 2013.

pdf icon Young, T. 2012. Using a protease test to inform wound care treatment decisions

 Haycocks, 2012. Assessing chronic diabetic foot wounds for elevated protease levels

 Hodgson, 2012. Clinical skills of tissue viability nurse versus Woundchek to detect elevated protease activity (EPA)

 Serena, T. et al. 2012 Preliminary results: Testing for elevated protease activity in clinical practice

 Johnstone, 2012. Case Studies: Testing for and treating EPA

 Cullen, B. et al 2012. Targeted use of Collagen/ORC improves clinical outcome

pdf icon Serena, T. et al. 2011. Protease activity levels associated with healing status of chronic wounds

pdf icon Snyder, R. et al. 2011.The importance of proteases in wound healing and wound assessment


Dr. Läuchli, Dr. Anichini, Dr. Dowsett, and Prof. Duteille, EWMA 2013 EPA, guiding treatment decisions for improved clinical results and cost effective care

Dr. Serena, Dr. Fletcher, and Dr. Läuchli, EWMA 2012 Testing for EPA, the arrival of wound diagnostics

Dr. Thoms, Training Event 2012 Proteases: Background, Assessment, and Treatment of EPA in chronic wounds (in German)

The product information on this page is not intended for, or to be used by health care professionals or users in the United States